<DOC>
	<DOCNO>NCT00280514</DOCNO>
	<brief_summary>Penetration cefpirome moxifloaxacin abscess fluid human test . Patients abscess schedule drainage receive study drug ( single multiple dose ) , pus sample plasma sample collect analyzed High pressure liquid chromatography ( HPLC ) . Pharmacokinetics study drug pus plasma determine use pharmacokinetic model .</brief_summary>
	<brief_title>Plasma Abscess Fluid Pharmacokinetics Cefpirome Moxifloxacin After Single Multiple Dose Administration</brief_title>
	<detailed_description>Title : Plasma abscess fluid pharmacokinetics cefpirome moxifloxacin single dose multiple dose administration . Background : Extensive research field abscess treatment establish claim invasive drainage efficient mean resolve suppurative lesion . In particular , computer tomography-guided percutaneous abscess drainage repeatedly report advantageous compare invasive method . However , application percutaneous interventional method subject limitation . Coagulation abnormality consider contraindication , absence safe anatomic access route , presence fistula , severe inflammation organ , patient advance age likewise link low success rate percutaneous abscess drainage . From consideration , become evident percutaneous surgical abscess drainage alone satisfactory number patient suffer abscess/infected cyst-related disease . In patient antibiotic therapy administer bridge stable condition drainage perform . Therefore , eminent overall outcome patient select appropriate antibiotic . For purpose , model recently develop simulate concentration time-curve fosfomycin abscess fluid single dose multiple dos . Cefpirome moxifloxacin drug may use empiric therapy purulent infection . They may use monotherapy may combine , e.g . fosfomycin . Cefpirome 4th class cephalosporin broad spectrum ( gram positive gram negative pathogen ) , penetrate well soft tissue . Moxifloxacin new fluoroquinolone considerable antimicrobial spectrum , also penetrate excellently soft tissue . Based experience method result obtain recent study fosfomycin penetration abscess fluid , present pilot study set gain PK information penetration property cefpirome moxifloxacin abscess fluid abdominal cyst . Aim study : To determine pharmacokinetics cefpirome moxifloxacin abscess ( cyst ) fluid plasma single multiple dos . Study design : Pharmacokinetic pilot study . Drug concentration determine abscess liquid upon drainage plasma period eight hour . Study population : 20 Patients abscess abdominal cyst , schedule surgical computer tomography-guided drainage . Methods : 1 ) High pressure liquid chromatography 2 ) Analysis computer tomography ( CT ) image 3 ) Pharmacokinetic simulation model Study drug : Cefpirome ( Cefrom , Aventis ) : administer patient intravenously single multiple dose 2 g dissolve 100 mL distil water 20 minute . Moxifloxacin ( Avelox , Bayer ) : administer patient per os tablet single multiple dose 400 mg . Patients : A total 20 patient enrol study . They assign 2 group . Group 1 : single dose ( n = 12 ) , Group 2 : multiple dos ( n = 8 ) . Main outcome variable : The cefpirome moxifloxacin concentration abscess fluid measure . Considering plasma PK ratio surface volume ratio abscess , individual concentration-versus-time curve abscess ( cyst ) fluid calculate . Individual pharmacokinetic parameter determine abscess ( cyst ) fluid single dose steady state : AUC , AUC0-12/24h , Cmax , Tmax , t1/2ß , Cav ( s ) . Additional outcome variable : Plasma ( single dose steady state ) : AUC , AUC0-12/24h , Cmax , Tmax , t1/2ß , Cav ( s ) . Pus plasma : ratio AUC Cav ( s ) MIC , T &gt; MIC The following parameter determine possible : diameter pericapsular space enrichment contrast agent , degree contrast agent enhancement zone pu density , rate drug degradation pu body temperature vitro , pH-value pu , pu viscosity specific weight . Inconveniences risks patient : The following side effect may occur administration cefpirome : Hypersensitivity reaction , allergic skin reaction , exanthema , urticaria , pruritus , drug fever , anaphylactic reaction , anaphylactic shock , interstitial nephritis , nausea , vomit , abdominal pain , diarrhoea , pseudomembraneous colitis , elevation liver enzymes serum creatinine , thrombocytopenia , eosinophilia , hemolytic anemia , granulocytopenia , agranulocytosis , local irritation pain site injection , dysgeusia . The following side effect may occur administration moxifloxacin : Often occasionally : Nausea , diarrhea , vomit , dyspepsia , QT-prolongation , elevation AST , ALT , bilirubin , gamma GT , amylase , leucocytopenia , decrease prothrombin , eosinophilia , thrombocythemia , thrombocytopenia , anemia , abdominal head pain , dizziness , dysgeusia ; unfrequent : asthenia , candidosis , thoracal back pain , discomfort , leg pain , anaphylactic reaction , anaphylactic shock , insomnia , vortex , nervousness , tremor , paresthesia , discomposure , depression , hallucination , depersonalization , ataxia , xerostomia , flatulence , obstipation , anorexia , stomatitis , glossitis , tachycardia , edema , hypertension , palpitation , QT-prolongation , syncope , atrial fibrillation , angina pectoris , vasodilatation , hypotension , ventricular arrhythmia , torsade de pointe , hyperglycemia , hyperlipidemia , elevation prothromin , icterus , arthralgia , myalgia , tendonitis , rash , pruritus , perspiration , urticaria , xerodermia , amblyopia , tinnitus , vaginitis , hepatitis , ataxia , tendon rupture , hypernatremia , hypercalcemia , neutropenia , hemolysis , transient loss vision . Total blood loss limit maximum 85 mL , usually well tolerated patient . Risk/benefit assessment : CT abscess drainage represent standard diagnosis therapeutic procedure . Therefore , risk associate CT abscess drainage ascribe study procedure . Single multiple dos cefpirome ( maximum 14 dos ) moxifloxacin ( maximum 7 dos ) normally well tolerated side effect . Ongoing therapy affect change study procedure . In summary , risk confer patient study procedure appear minimal .</detailed_description>
	<mesh_term>Abscess</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Cefpirome</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Female male , age 18 90 year . Written informed consent . Abscess formation abdominal cyst schedule drainage . Plasma creatinine &lt; 1.5 mg/dL Pregnancy lactation . Hemodialysis hemofiltration Allergy hypersensitivity study drug Massive edema hypernatremia Reduced liver function ( ChildPugh A , B , C ) Relevant prolongation QTinterval CNSdiseases predispose cramp</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2005</verification_date>
	<keyword>abscess</keyword>
	<keyword>penetration</keyword>
	<keyword>antibiotic</keyword>
	<keyword>cefpirome</keyword>
	<keyword>moxifloxacin</keyword>
	<keyword>abdominal cyst</keyword>
</DOC>